Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics (GLYC)
NASDAQ:GLYC
Holding GLYC?
Track your performance easily
GLYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.14 - $3.53
Previous Close$0.38
Volume3.61M
Average Volume (3M)19.40M
Market Cap
$24.67M
Enterprise Value$2.72M
Total Cash (Recent Filing)$22.40M
Total Debt (Recent Filing)$448.77K
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Nov 07, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding64,483,958
10 Day Avg. Volume119,421,351
30 Day Avg. Volume19,403,752
Standard Deviation0.41
R-Squared0.06
Alpha-0.00138
Financial Highlights & Ratios
Price to Book (P/B)1.23
Price to Sales (P/S)2467.16
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue272.03
Enterprise Value/Gross Profit272.03
Enterprise Value/Ebitda-0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
GlycoMimetics News
PremiumCompany Announcements
GlycoMimetics Announces Merger with Crescent Biopharma
PremiumCompany Announcements
GlycoMimetics Announces Strategic Review and Restructuring Plan
Bulls Say, Bears Say
Bulls Say
Clinical Study And Potential ApprovalThe National Cancer Institute is conducting a Phase 2/3 study in newly diagnosed adults with AML who are fit for intensive chemotherapy, which could offer an opportunity for approval in frontline patients.
Positive Subset Data And SafetyGlycoMimetics announced some positive subset data when it reported comprehensive results from its randomized, double-blind, placebo-controlled, global, pivotal Phase 3 study of uproleselan in relapsed or refractory acute myeloid leukemia (AML).
Strategic Advancements And Market PotentialGMI-1687 could be an attractive product for a large cap or specialty pharma company due to the potential size of the addressable market.
Bears Say
Clinical TrialsThe pivotal Phase 3 trial of uproleselan in patients with relapsed/refractory acute myeloid leukemia did not achieve its primary goal of improving overall survival.
Regulatory ChallengesThe company needs to conduct an additional clinical trial to satisfy regulatory requirements for uproleselan, extending the timeline for potential approval.
Workforce ReductionGlycoMimetics has significantly reduced its workforce by approximately 80% as part of a strategic review and restructuring plan.
---
Ownership Overview
12.64% Insiders
4.98% Mutual Funds
0.19% Other Institutional Investors
77.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GLYC FAQ
What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $0.14 and its highest was $3.53 in the past 12 months.
What is GlycoMimetics’s market cap?
Currently, no data Available
When is GlycoMimetics’s upcoming earnings report date?
GlycoMimetics’s upcoming earnings report date is Nov 07, 2024 which is in 3 days.
How were GlycoMimetics’s earnings last quarter?
GlycoMimetics released its earnings results on Aug 01, 2024. The company reported -$0.165 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.005.
Is GlycoMimetics overvalued?
According to Wall Street analysts GlycoMimetics’s price is currently Overvalued.
Does GlycoMimetics pay dividends?
GlycoMimetics does not currently pay dividends.
What is GlycoMimetics’s EPS estimate?
GlycoMimetics’s EPS estimate is -$0.11.
How many shares outstanding does GlycoMimetics have?
GlycoMimetics has 64,483,955 shares outstanding.
What happened to GlycoMimetics’s price movement after its last earnings report?
GlycoMimetics reported an EPS of -$0.165 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GlycoMimetics?
Currently, no hedge funds are holding shares in GLYC
---
GlycoMimetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GLYC Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $170.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.68%
12-Months-Change
Fundamentals
Return on Equity
-104.49%
Trailing 12-Months
Asset Growth
-60.50%
Trailing 12-Months
Company Description
GlycoMimetics
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
---
GLYC Earnings Call
Q4 2024
0:00 / 0:00
---
GLYC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Oncternal Therapeutics
―
Sutro Biopharma
―
Fate Therapeutics
―
Best Analysts Covering GLYC
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-17.88%
reiterated a buy rating 7 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -17.88% per trade.
---